Compare iShares 1 3 Year Treasury Bond ETF (SHY) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 1 3 Year Treasury Bond ETF vs Smith & Nephew plc — how do they compare? iShares 1 3 Year Treasury Bond ETF trades at $81.88, while Smith & Nephew plc trades at $30.05 (market cap $12.54B). The key difference: Smith & Nephew plc pays a 2.65% dividend while iShares 1 3 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals.
| SHY | SNN | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $83.18 | $38.70 |
52-Week Low | $81.77 | $28.73 |
Market Cap | — | $12.54B |
Enterprise Value | — | $15.57B |
Dividend Yield | — | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SHY (iShares 1-3 Year Treasury Bond ETF) trades at $81.94 with minimal daily movement (+0.1%). The technical picture shows bearish momentum with moving averages signaling caution, though oscillators remain neutral. Recent institutional activity indicates growing interest, with Barry Investment Advisors increasing their position by 48.1% in Q2 2026. Treasury yield fluctuations and inflation data remain key drivers for this short-term bond ETF.
Outlook remains tied to Federal Reserve policy and inflation trends. The ETF offers stability with regular dividends but faces headwinds from rising yields. Investment opportunity lies in capital preservation during market volatility, though rising rates could pressure short-term bond prices. Key risks include interest rate sensitivity and macroeconomic policy shifts.
SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.
The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
